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Abstract 29 
Prostate cancer is the primary male cancer with increasing global incidence rates making this 30 
malignancy a significant healthcare burden. Androgens promote normal prostate maturity but 31 
also influence the development and progression of prostate cancer. Intriguingly, evidence 32 
now suggests endogenous and exogenous oestrogens, in the form of phytoestrogens, may be 33 
equally as relevant as androgens in prostate cancer growth.  The prostate gland has the 34 
molecular mechanisms, catalysed by steroid sulphatase (STS), to unconjugate and utilise 35 
circulating oestrogens. Furthermore, prostate tissue also expresses enzymes essential for local 36 
oestrogen metabolism, including aromatase (CYP19A1) and 3β- and 17β-hydroxysteroid 37 
dehydrogenases. Increased expression of these enzymes in malignant prostate tissue 38 
compared to normal prostate indicates oestrogen synthesis is favoured in malignancy and thus 39 
may influence tumour progression. In contrast to previous reviews, here we comprehensively 40 
explore the epidemiological and scientific evidence on how oestrogens impact prostate 41 
cancer, particularly focusing on pre-receptor oestrogen metabolism and subsequent molecular 42 
action. We analyse how molecular mechanisms and metabolic pathways involved in 43 
androgen and oestrogen synthesis intertwine to alter prostate tissue. Furthermore, we 44 
speculate on whether oestrogen receptor status in the prostate affects progression of this 45 
malignancy. 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
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Introduction 54 
In the UK prostate cancer is the number one male malignancy accounting for 25% of all new 55 
cancer diagnoses in men (Siegel, et al. 2012). In 2011, there were almost 42,000 new cases 56 
with an age-standardised incidence rate of 104.7 per 100,000. Prostate cancer is the second 57 
leading cancer killer in UK men and 4
th
 most common cause of cancer death in the general 58 
population. Similarly, in Europe prostate cancer is the most common cancer in males and 59 
third most common cancer overall (Jacob and Henrik 2006) . It is the third most common 60 
cause of cancer deaths in men and sixth overall. Currently, prostate cancer is the second most 61 
common cancer in males worldwide after lung cancer. However, it is predicted that prostate 62 
cancer will become the most common cancer in men globally (Parkin, et al. 2001).  63 
Survival statistics from prostate cancer have improved dramatically over the last four decades 64 
which may be attributed to earlier detection and treatment granted by prostate specific 65 
antigen (PSA) testing and transurethral resection of the prostate (TURP). The UK 10-year 66 
survival has improved from 25% when diagnosed in 1970 to 84% in 2010 (Quaresma, et al. 67 
2015). Prostate cancer primarily affects the elderly with 99.9% of patients diagnosed over the 68 
age of 50 and the mean age at diagnosis being 73 (Parkin, et al. 1997). Furthermore, from 69 
autopsy studies of non-cancer-related deaths, there is histological evidence of prostate 70 
neoplasms in more than 50% of men in their 50s  (Sakr, et al. 1993). As average male life 71 
expectancy gradually increases, it is foreseeable that men will live longer with the disease 72 
and may experience a poorer quality of life. 73 
There are significant geographical variations between prostate cancer incidences around the 74 
world with up to a 24-fold difference between the regions with the highest rates (in Australia, 75 
North America and Western Europe) and the lowest rates (in India, Japan and China) (Center, 76 
et al. 2012). While some of the discrepancies might be explained by disparities in healthcare 77 
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access, diagnostic methods, screening programmes and reporting systems; environment and 78 
lifestyle remain considerable factors. Studies comparing the incidence of prostate cancer in 79 
first and second generation Asian immigrants to USA with age-matched controls in their 80 
native countries have found that migrants travelling from low risk countries to high risk 81 
countries adopt the higher risk (Cook, et al. 1999). This advocates that environmental risk 82 
factors may have a higher precedence than genetic associations in determining risk of 83 
prostate cancer. Furthermore, environmental and lifestyle factors, diet in particular, 84 
fundamentally alter endogenous hormones including sex steroids (Barazani, et al. 2014). 85 
Indeed, factors such as smoking, increased physical exercise and a vegetarian diet increased 86 
serum androgen concentrations in British men while obesity, high fat diet and sedentary 87 
occupation reduced serum androgen concentrations (Allen et al. 2002). Such hormonal 88 
changes have the propensity to subsequently affect tumour initiation and progression 89 
(Kolonel, et al. 2004). 90 
 91 
Sex Steroids and Prostate Cancer 92 
Both males and females produce sex steroid hormones; the predominant androgens are 93 
testosterone and the more biologically active dihydrotestosterone (DHT) and the predominant 94 
oestrogens are oestrone (E1) and the more biologically active oestradiol (E2). However, the 95 
ratio of the two hormones differs between the sexes significantly. In the prostate, androgens 96 
are required for normal development and function. However, the role of oestrogens in normal 97 
prostate development is ill defined as biochemical mechanisms are still under investigation;  98 
the current dogma being that oestrogens are involved in the differentiation of epithelial tissue 99 
(Chen, et al. 2012; Francis, et al. 2013) and regulation of prostatic angiogenesis (Montico, et 100 
al. 2013).  101 
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 102 
Androgens have been implicated in prostate carcinogenesis since 1941 when Huggins 103 
published his Nobel winning study showing testosterone injections exacerbate prostate cancer 104 
in patients with late-stage disease and androgen deprivation alleviated the disease (Huggins 105 
and Hodges 1941), this suggested prostate cancer as an androgen-dependent malignancy. The 106 
primary source of androgens in males is testosterone secreted by the testicles, however, the 107 
adrenal glands secrete 100-500 times greater amounts of dehydroepiandrostrone sulphate 108 
(DHEAS), a testosterone precursor which can be converted peripherally in the prostate into 109 
testosterone and DHT (Labrie, et al. 2005). Androgen ablation therapy is initially successful 110 
in the vast majority of prostate cancers but relapse is common as tumours become castration 111 
resistant; they still however continue to express androgen receptors which respond to very 112 
low concentrations (as low as 10 pM) of peripherally synthesised testosterone and DHT 113 
(Chen, et al. 2004; Mohler, et al. 2004). Using microarray experiments on LNCaP and 114 
LAPC4 cell lines, Chen et al. (2004) showed an increase in androgen receptor mRNA and 115 
protein expression in vitro and in vivo in castrated xenograft murine models which correlated 116 
with tumour growth. Increased expression of androgen receptors amplified signals from low 117 
levels of androgen ligands to confer castration resistance. Mohler et al (2004) demonstrated 118 
using immunostaining and radioimmunoassays that activation of androgen receptors occur 119 
even in human prostate cancer samples retrieved from chemically castrated patients. This 120 
explains why surgical or medical castration is not 100% effective.  121 
Previously, second-line hormonal therapy has proven to improve survival in patients with 122 
castration-resistant disease, both before and after docetaxel chemotherapy. Both inhibition of 123 
steroidogenic enzyme CYP17A1 using abiraterone and androgen receptor antagonism by 124 
enzalutamide have successfully ablated continued androgen receptor activation and prostate 125 
cancer growth (Beer , et al. 2014; de Bono , et al. 2011; Ryan , et al. 2013; Scher , et al. 126 
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2012). However, as with other androgen ablation therapy, resistance to abiraterone and 127 
enzalutamide inevitably develops. 128 
 129 
Even though molecular mechanisms were not elucidated, oestrogens were traditionally 130 
considered to protect against prostate cancer. Therapeutic use of oestrogens was based on 131 
their anti-androgenic effects. Huggins reported exogenous oestrogens had protective 132 
properties mediated by a negative feedback effect on the hypothalamic-pituitary-gonadal 133 
(HPG) axis which reduced stimulation for androgen secretion from the testes (Huggins and 134 
Hodges 1941). Diethylstilbestrol (DES), a synthetic non-metabolised oestrogen is still used in 135 
certain clinics as a non-first line therapy to chemically castrate patients with metastatic 136 
prostate cancer (Bosset, et al. 2012; Clemons, et al. 2013). DES negatively feedbacks on the 137 
pituitary gland to reduce secretion of luteinizing hormone which reduces the stimulus for the 138 
testes to synthesise sex hormones  In addition to the effects oestrogens have on the HPG axis, 139 
demonstrated by quantitative PCR,DES inhibits androgen-stimulated telomerase activity and 140 
gene expression  and induces apoptosis in LNCaP and PC3 prostate cancer cell lines in both 141 
the presence and absence of androgens (Geier, et al. 2010). On the contrary, while DES is 142 
still licensed in the UK for treatment of prostate cancer it is infrequently used as secondary 143 
treatment due to the accompanied high rates of cardiovascular toxicity (Malkowicz 2001). 144 
Importantly, the interactions of oestrogens on androgen receptors should be considered. For 145 
example, E2 can activate both wildtype and, with greater efficacy, mutated (T877A) androgen 146 
receptors in LNCaP cells (Susa et al J Cell Physiolog 2015; Yeh et al. 1998; Veldscholte et al 147 
J Steroid Biochem Mol Biol. 1992). Mutations of the androgen receptor are uncommon in the 148 
early stages of prostate cancer but are much more frequent in late-stage disease. In one study, 149 
out of 99 patients diagnosed with early stage prostate cancer none were found to have 150 
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mutations in the androgen receptor. On the contrary, eight tumours out of 38 patients with 151 
advanced prostate cancer were found to harbour androgen receptor mutations (Marcelli, et al. 152 
2000; Brooke and Bevan 2009). There is, however, mounting evidence that oestrogens may 153 
be involved in the initiation and progression of prostate cancer, although compelling evidence 154 
confirming oestrogen binding affinity to AR is lacking.   155 
 156 
Impact of Endogenous Oestrogens in Prostate Cancer 157 
Males are exposed to a high oestrogen/androgen (E/T) ratio twice in their lifetime. The first is 158 
as a foetus, during the third trimester when the maternal E2 levels increase and foetal 159 
androgen levels decrease. Raised E2 levels stimulate the developing epithelial cells of the 160 
prostate to proliferate but also cause morphological changes. For example, the prostate glands 161 
of neonatal rats and mice show abnormal proliferation and cell structure when the pregnant 162 
mother is injected with E2. (Wernert, et al. 1990). This early exposure may imprint 163 
intracellular changes by modulating expression pathways of steroid enzymes and receptors  164 
as shown in rat models where the response to endogenous androgens and oestrogens becomes 165 
abnormal, thus predisposing the animal to prostate cancer after sexual maturation (Rajfer and 166 
Coffey 1978). Moreover, studies in mice show that when exposed to high levels of oestrogens 167 
in utero, foetal prostate tissue develops abnormalities including intraepithelial neoplasia and 168 
predisposition to carcinogenesis in adult life (Prins, et al. 2006). This hypothesis is supported 169 
by epidemiological evidence obtained from African-American men having twice as high a 170 
risk of developing prostate cancer than comparable Caucasian men which correlates with 171 
African-American women having a higher serum oestrogen level during pregnancy compared 172 
to Caucasian women (Henderson, et al. 1988).  173 
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The second time men are exposed to a high E/T ratio is during old age when serum 174 
testosterone decreases, partly due to a dampened HPG axis and partly due to reduced Leydig 175 
cell function in the testes. In addition to this, sex hormone-binding globulin (SHBG), which 176 
has a higher affinity to testosterone than E2 (Knochenhauer, et al. 1998), also increases with 177 
age which further decreases free serum testosterone relative to free serum E2 (Samaras, et al. 178 
2012). Furthermore, there is evidence that E1 and E2 not only remain at the same level, but in 179 
fact increase with age even when accounted for BMI and other metabolic diseases (Jasuja, et 180 
al. 2013).  While the evidence for an association between serum oestrogen concentration and 181 
risk of prostate cancer is unclear and inconsistent, increased serum oestrogen concentrations 182 
may stimulate the prostate stroma and epithelia to proliferate and subsequently become 183 
neoplastic. Indeed a higher oestrogen:androgen ratio stimulates proliferation of normal 184 
prostate stromal (PrSC) and normal epithelial (PrEC) cell lines in vitro (King, et al. 2006).  185 
 186 
Another interesting population which is exposed to a high E/T ratio are transsexual male to 187 
female individuals. Often in this group of former males, individuals are orchiectomised and 188 
then supplemented with anti-androgens to relinquish masculine secondary sex characteristics. 189 
They are also supplemented with oestrogens to acquire and enhance feminine characteristics. 190 
Their prostates, however, remain unadulterated. A study observing such a cohort of 191 
transsexual persons for over 30 years has not identified any increase in risk for prostate 192 
cancer (Gooren and Morgentaler 2014). However the study has suggested that when 193 
presenting these patients are more likely to be diagnosed with a later stage disease. One 194 
limitation admitted by the authors is that the majority of the cohort has not reached the mean 195 
age at which prostate cancer is typically diagnosed (Gooren and Morgentaler 2014). 196 
Observations made to this cohort over the next two or three decades will be most 197 
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enlightening in ascertaining whether oestrogens have any significant effects in the 198 
development of prostate cancer. 199 
 200 
Oestrogen Metabolism in Adipose and Prostate Cancer 201 
 202 
While in pre-menopausal females the primary source of oestrogens are the ovaries, in males 203 
there is no central organ which produces substantial quantities of E2. Instead, peripheral 204 
conversion of oestrogen precursors is the main source of oestrogen in men. Local synthesis of 205 
E1 and E2 is regulated by a plethora of enzymes. DHEA secreted from the zona reticularis of 206 
the adrenal glands, and stored in the blood as a reservoir as DHEAS, is the ultimate 207 
precursor. Adipose tissue is another notable source of oestrogen synthesis (Cui, et al. 2013). 208 
White adipose tissues (the predominant type in obesity) express significant quantities of 209 
cytochrome P450 aromatase enzyme (CYP19A1) in the abdominal adipose fat of male human 210 
samples, which is the final catalyst in the conversion of androgens to oestrogens (Polari, et al. 211 
2015; Wang, et al. 2013). There is also a positive correlation between the amount of visceral 212 
adipose tissue and serum E2 levels as shown in a study of 229 man with a mean age of 53.6 213 
years where visceral fat was measured using magnetic resonance imaging (Gautier, et al. 214 
2013).  215 
 216 
There have been conflicting reports as to whether obesity is a risk factor for prostate cancer 217 
as some suggest it decreases risk while others have found the opposite. Allott et al. have 218 
summarised the findings published between 1991 to 2012 in their review and conclude 219 
obesity is associated with aggressive prostate cancer (Allott, et al. 2013). There is further 220 
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robust evidence that obese patients are more likely to present with aggressive high-grade 221 
prostate cancer (De Nunzio, et al. 2013; Vidal, et al. 2014). It is possible that the risk 222 
associated with obesity may in fact be due to elevated circulating oestrogen levels secondary 223 
to increased adipose deposition. If this is the case, it would parallel the effects of oestrogen 224 
that have been observed in colorectal cancer where oestrogen exposure in the form of 225 
hormone replacement therapy or oral contraceptives are initially protective against colorectal 226 
cancer but when patients present, they present with a later stage disease (Foster 2013). The 227 
intra- and extracellular handling and metabolism of oestrogens within the prostate gland may 228 
clarify what effects oestrogens have on tumours. However, studies are lacking regarding the 229 
exact intra-tumoural metabolism of oestrogens in prostate cancer cells and human prostate 230 
cancer tissue. 231 
 232 
Impact of Exogenous Oestrogen on Prostate Cancer 233 
Exogenous oestrogen intake and subsequent availability to the prostate should be considered 234 
when determining whether oestrogens affect the development and progression of prostate 235 
cancer. A Western diet comprising of high meat, saturated fat, and dairy products has been 236 
associated with increased risk of prostate cancer as highlighted by numerous epidemiological 237 
studies (Grönberg 2003; Howell 1974; Whittemore, et al. 1995). Additionally, it has been 238 
observed that such a Western diet is more likely to cause men diagnosed with prostate cancer 239 
to die from the disease when compared to a diet rich in fruits, vegetables, and whole grain 240 
cereals (Yang, et al. 2014). Supporting this, it has been widely speculated that dietary 241 
oestrogenic compounds from plant sources, termed phytoestrogens, are protective against 242 
prostate cancer and are the reason behind lower incidence rates in East Asia where per capita 243 
consumption of phytoestrogen-rich foods, such as soya beans, are considerably higher than 244 
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the Western world (Adlercreutz, et al. 2000; Goetzl, et al. 2007; Strom, et al. 1999). It is 245 
possible that phytoestrogens reduce the risk of prostate cancer through multiple mechanisms. 246 
In rodent models phytoestrogens can upregulate SHBG synthesis in the liver leading to a 247 
higher circulating concentration (Pilšáková, et al. 2010). Increased SHBG is anti-androgenic 248 
as it binds to free testosterone with a higher affinity than oestrogens (Knochenhauer et al. 249 
1998) implementing a net reduction of testosterone relative to E2 (Ronde, et al. 2005). This 250 
reduction in androgen is thought to be important in the reduction of risk. In addition to 251 
chelation of free testosterone via SHBG, phytoestrogens have a negative feedback effect on 252 
the HPG axis directly leading to reduced secretion of luteinising hormone and consequently 253 
reduced stimulation of androgen and oestrogen synthesis (Goetzl et al. 2007). 254 
 255 
 Phytoestrogen compounds are similar enough to endogenous oestrogens to be able to bind to 256 
oestrogen receptors (ER) and evoke ligand-specific intracellular responses (Usui 2006). 257 
Preference for different types of nuclear ER varies between phytoestrogens (see section on 258 
oestrogen receptors). Isoflavones and coumestans are two main categories of phytoestrogens 259 
and are structurally similar to E2 (Figure 1). The prostate cancer cell lines LNCaP and DU145 260 
are more sensitive to apoptotic factors when treated with isoflavones in vitro. A dose-261 
response relationship between concentration of biochanin A and apoptosis was observed 262 
using cytotoxicity and lactate dehydrogenase release assays, flow cytometry and fluorescence 263 
microscopy (Szliszka, et al. 2013). Coumestans are able to induce caspase-dependent 264 
apoptosis in LNCaP, DU145 and PC3 cells. When treated with wedelolactone, a plant derived 265 
coumestan, there was dose-dependent apoptosis in androgen-sensitive cell lines (LNCaP) and 266 
androgen-independent cell lines (DU145 and PC3). However, normal non-cancerous PrEC 267 
prostate epithelial cells were not affected as harshly showing 90% cell viability compared to 268 
circa 20% in cancerous cell lines at concentrations of 30µM. (Sarveswaran, et al. 2012). 269 
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While in vitro evidence argues that phytoestrogens are protective against prostate cancer, 270 
clinical trials looking at the relationship between consumption of dietary phytoestrogens and 271 
progression of prostate cancer have been inconclusive (Goetzl et al. 2007). One double blind 272 
randomised control trial in which 81 healthy men were either given a soy protein drink with 273 
high isoflavone concentration (83mg/day) or a drink with low isoflavone concentration 274 
(3mg/day) showed no significant difference in PSA over 12 months (Adams, et al. 2004). 275 
Another trial offering men with confirmed prostate cancer who had either failed 276 
medical/surgical therapy or had chosen active surveillance a high dose (450mg/day) oral 277 
isoflavone supplement for 6 months showed only a clinically insignificant improvement in 278 
PSA in the active surveillance group with no difference in the failed therapy group (deVere 279 
White, et al. 2004). Furthermore, a study following up 3628 men with diagnosed prostate 280 
cancer for a median duration of 11.5 years showed an increased risk of advanced prostate 281 
cancer (HR: 1.62) but a reduced risk of non-advanced prostate cancer (HR: 0.88) in the 282 
higher dietary intake of isoflavones group. Dietary intake of phytoestrogens was measured 283 
using a validated food frequency questionnaire and so exact doses of phytoestrogens are 284 
subject to variation (Reger et al. 2015). This preliminary evidence could infer that dietary 285 
phytoestrogens might protect against initiation of prostate cancer, however may promote the 286 
progression of advanced prostate cancer. 287 
  288 
 289 
 290 
Steroid metabolism in the prostate 291 
Androgens 292 
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The metabolism of oestrogens and oestrogen precursors is important for availability of 293 
biologically active E2 to prostate cancer cells. Oestrogens are synthesised from androgens 294 
which themselves are synthesised from progestogens (Khurana 2008). In addition to 295 
circulating androgens secreted from the testes, normal prostate tissues have the potential to 296 
produce androgens from circulating C19 steroids DHEA and androstenedione (Figure 2). 297 
There have been conflicting reports on the possibility of prostate cancer to synthesize 298 
androgens de novo through the conversion of progestogens via cytochrome P450 17A1 (17-299 
hydroxylase and 17, 20 lyase enzyme [CYP17A1]). In prostate cancer, the expression of 300 
cytochrome P450 17A1 was reportedly increased in LNCaP and LuCaP cells and human 301 
prostate tissue samples ascertained by PCR and immunoblotting (Locke, et al. 2008; 302 
Montgomery, et al. 2008); however not all studies support this (Ellem and Risbridger 2009; 303 
Hofland, et al. 2010). Although DHT formation from cholesterol was detected using mass 304 
spectrometry in castration-resistant prostate cancer (CRPC)  models in one study (Locke et al. 305 
2008) these steroid fluxes have not been confirmed quantitatively to date in either in vitro or 306 
in vivo models. 307 
 308 
Another key enzyme in the synthesis of biologically active androgens and oestrogens is 3-309 
betahydroxysteroid dehydrogenase (3β-HSD) which converts dehydroepiandrosterone and 310 
androstenediol to androstenedione and testosterone, respectively (White, et al. 2013). 3β-311 
HSD is expressed in the normal human prostate, with immunoblotting revealing that the 312 
highest concentrations are found in basal epithelial cells (Luu-The, et al. 2008). Certainly, in 313 
mouse xenograft studies using the CRPC LAPC4 cell line, expression of 3β-HSD is increased 314 
within the tumour in addition to AKR1C3 and 17β-HSD3 (Chang, et al. 2011), although its 315 
mRNA expression almost completely mutually excludes that of CYP17A1 (Hofland et al. 316 
2010).   317 
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 318 
Inhibitors of 3β-HSD have been explored as an androgen deprivation technique as they are 319 
effective in decreasing proliferation in androgen sensitive LNCaP or CRPC cell lines 22Rv1, 320 
VCaP and PC346C in vitro (Evaul, et al. 2010; Kumagai, et al. 2013). Furthermore, 321 
abiraterone was found to inhibit 3β-HSD activity in addition to CYP17A1 in prostate cancer 322 
cell lines and isolated yeast microsomes (Li, et al. 2012). This mechanism might rely on 323 
abiraterone being converted to the more active ∆(4)-abiraterone (D4A) within the prostate 324 
gland  by 3β-HSD itself (Li, et al. 2015b). Further research into 3β-HSD inhibition are 325 
currently being pursued, however alternative pathways which bypass androstenedione 326 
synthesis exist and so 3β-HSD function is not strictly necessary. 327 
 328 
 329 
An alternative pathway has been demonstrated by which synthesis of DHT within the 330 
prostate may bypass testosterone and instead be synthesised by reduction of androstenedione 331 
by 5α-reductase SRD5A1 to 5α-androstanedione which is converted to DHT by 17β-HSD5. 332 
Mass spectrometry has shown that even in patients on anti-androgen therapy with very low 333 
serum testosterone levels, intratumoral DHT concentrations remain at the pre-treatment level 334 
(Chang et al. 2011; Sharifi and Auchus 2012). 17β-HSD-5, also known as AKR1C3, appears 335 
to be the key enzyme responsible for intratumoural androgen production in CRPC. Its 336 
expression in LNCaP, DU145 and PC3 cellsare potently stimulated by androgen deprivation 337 
in vitro and in humans in vivo (Ellem and Risbridger 2009; Ellem, et al. 2004) and this 338 
secures continued production of testosterone and DHT from circulating adrenal androgens. 339 
Local growth factor activin A was shown to be a key intermediate in the castration-induced 340 
rise of AKR1C3 expression levels and intratumoural testosterone production as observed in 341 
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LNCaP, VCaP and PC3 cells. The concentration of activin A and testosterone were also 342 
shown to be increased in the cultured supernatants, as measured by ELISA and mass 343 
spectrometry  (Hofland, et al. 2011). 17β-HSD-5 has also been implicated in ezalutamide 344 
resistance to anti-androgen therapy. Knockdown of 17β-HSD-5 using shRNA or inhibition 345 
with indomethacin has shown to resensitise enzalutamide-resistant cells in vitro and in vivo 346 
(Liu, et al. 2015). 347 
Peripheral Oestrogen Metabolism in Prostate Cancer 348 
As mentioned previously, aromatase is a key enzyme required for oestrogen synthesis from 349 
androgen precursors. Aromatase converts androstenedione and testosterone to E1 and E2, 350 
respectively (White et al. 2013). The local synthesis of E2 within the prostate has previously 351 
been debated as not all experiments have identified aromatase expression in normal prostate 352 
tissue (Ellem et al. 2004). However, it has been demonstrated in human samples by substrate 353 
conversion assays and mass spectrometry that E2 synthesis does occur in prostate cancer cells 354 
(and benign prostatic hyperplasia) via aromatisation (Ellem and Risbridger 2009; Härkönen 355 
and Mäkelä 2004). In normal prostate, aromatase is expressed by the stromal tissue but not 356 
the epithelial cells, however once malignant, epithelial cells also express aromatase (Ellem 357 
and Risbridger 2007). Aberrant expression and activity of aromatase is crucial in the 358 
pathophysiology of endometrial and breast cancers where an imbalance of oestrogen is a key 359 
factor in tumour growth (Chen 1998; Cunha 1994). As with the developmental similarities 360 
between breast and prostate tissues (Ellem and Risbridger 2010), abnormal aromatase activity 361 
also plays a major role in breast and prostate tumourigenesis (Ellem and Risbridger 2010). 362 
Tumourigenic growth factors including epidermal growth factor and transforming growth 363 
factor-1 can modulate aromatase activity in androgen-sensitive LNCaP cells lines leading to 364 
decreased oestrogen synthesis (Block, et al. 1996). Furthermore, the expression of aromatase 365 
is up to 30-fold greater in metastatic prostate cancer compared to primary tumours 366 
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(Miftakhova, et al. 2016). In addition, overexpression of aromatase increased the progression 367 
of bony metastasis in xenograft experiments where nude mice were injected with PC3 cell 368 
lines transfected to overexpress aromatase (Miftakhova, et al. 2016).  Consequently, the use 369 
of aromatase inhibitors for the treatment of prostate cancer has been investigated many times 370 
in patient cohorts. The first generation aromatase inhibitor aminoglutethimide is non-371 
selective and showed poor objective responses including serum PSA levels and disease 372 
stability in some studies while showing a significant increase in survival in others (Santen, et 373 
al. 1997). One study treated 58 castrated men with advanced prostate cancer resistant to 374 
conventional therapy with 500-750mg daily aminoglutethimide; 11 men showed an objective 375 
response with a mean remission of 10 months and a further two showed disease stabilisation 376 
for a mean seven months (Murray and Pitt 1985). The second generation aromatase inhibitor, 377 
4-hydroxyandrostenedione showed good subjective responses in 18 out of 25 patients with 378 
advanced CRPC, particularly alleviation of bone pain in prostate metastases.  However the 379 
objective responses were still poor with a reduction in tumour volume seen in only three 380 
patients and all patients progressed to have skeletal metastasis.  (Davies, et al. 1992). A Phase 381 
II clinical study looking at the effects of oral letrozole, a third-generation aromatase inhibitor 382 
more commonly used in the treatment of hormone-dependent breast cancer, in 43 men with 383 
CRPC showed no significant disease regression with serum PSA decreasing by more than 384 
50% in only one patient and decreasing by less than 50% in one further patient  (Smith, et al. 385 
2002). A very similar conclusion was drawn from clinical studies looking at anastrazole, 386 
another third generation aromatase inhibitor, where out of 14 patients with CRPC none 387 
showed a decrease in serum PSA and mild bone pain relief was reported by only two patients 388 
(Santen, et al. 2001). While aromatase is of utmost importance in local oestrogen synthesis, it 389 
appears as though therapeutic approaches targeting aromatase may be futile in treating 390 
prostate cancer. An alternative possibility is that E2 is not synthesised from androgens within 391 
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the prostate but instead is converted from systemic sulphated E1 within the prostate via 392 
steroid sulphatase (STS).  393 
 394 
STS is widely expressed in almost all peripheral tissues and is responsible for hydrolysing 395 
sulphate moieties off of circulating sulphate-conjugated steroids in order to make them 396 
biologically active (Mueller, et al. 2015). Oestrone sulphate (E1S) is the most abundant 397 
circulating oestrogen in adult humans (Muir, et al. 2004) with plasma levels between 2-398 
4nmol/L in men (Mueller et al. 2015) and while oestradiol sulphate also exists, plasma levels 399 
are very low. Furthermore, serum E1S levels have been correlated with increased risk of 400 
prostate cancer. In a cohort study of 5995 men aged over 65 where the mean serum E1S levels 401 
in the 275 patients who developed prostate cancer was significantly higher than those who 402 
did not develop prostate cancer (Daniels, et al. 2010).  403 
 404 
Before sulphated oestrogens can be unconjugated by intracellular STS, transport of sulphated 405 
oestrogens into cells requires the expression of organic anion transporter peptides (OATP) 406 
(Raftogianis, et al. 2000) and indeed several different OATPs involved in the transport of 407 
oestrone sulphate are expressed in prostate cancers (Buxhofer-Ausch, et al. 2013; Giton, et al. 408 
2015; Wright, et al. 2011). STS has been shown to be expressed in normal human prostate 409 
tissue (Reed, et al. 2005), prostate cancer cell lines LNCaP, DU-145 and PC3 (Nakamura, et 410 
al. 2006) and in primary prostate homogenates (Klein, et al. 1989). Furthermore, one study 411 
found that STS is expressed in the majority of localised prostate cancers showing higher 412 
expression in malignant tissues compared to benign (Nakamura, et al. 2006). The activity of 413 
STS has been proven within the human prostate for the desulphation of 414 
dehydroepiandrosterone sulphate (DHEAS) into DHEA, an androgen precursor (Farnsworth 415 
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1973). Moreover, E1 synthesis from desulphation of E1S within the prostate is putatively 10-416 
fold greater than synthesis via aromatase (Nakamura et al. 2006). The relevance of STS in 417 
cancer has been more extensively studied in breast cancer where there is significantly higher 418 
expression of STS than in normal breast (Utsumi, et al. 2000). Consequently, several STS 419 
inhibitors have been developed for the treatment of breast cancer, some of which have shown 420 
early promise (Stanway, et al. 2006). Moreover, first and second generation STS inhibitors 421 
have been effective pre-clinically against breast cancer (Foster et al. 2006; Foster et al. 2008; 422 
Purohit and Foster 2012). Meanwhile, investigations into the efficacy of STS inhibitors in 423 
prostate cancer have been undertaken. It has been observed that middle-aged rats treated with 424 
oral STS inhibitor, STX64 decreased conversion of E1S to E1 (Giton et al. 2015; Roy, et al. 425 
2013). Neither study presented evidence of STS inhibition affecting any proliferative markers 426 
of proliferation, however the latter study did demonstrate that STS inhibition in middle-aged 427 
rats prevented increase of prostate mass when treated with E1S + STX64 vs E1S alone where 428 
prostate mass increased (Giton et al. 2015). An alternative conjugate of circulating oestrogens 429 
is glucuronide (Raftogianis et al. 2000), however, research into oestrogen glucuronide 430 
transport into prostate cells and evidence of glucuronidase enzymes within the prostate is 431 
lacking. 432 
 433 
Conversion of E1 to E2 (and androstenedione to testosterone) requires 17-betahydroxysteroid 434 
dehydrogenase (17β-HSD) enzymes (White et al. 2013). 17β-HSDs enzymes are alcohol 435 
oxidoreductases which catalyse reduction (E1 to E2) and oxidation (E2 to E1) at carbon atom 436 
17. There are over 14 different isozymes of 17β-HSDs (17β-HSD 1-14) and certain 17β-437 
HSDs have a higher propensity to catalyse the reaction in a certain direction, for example 438 
17β-HSD-1 favours reduction whereas 17β-HSD-2 favours oxidation (Lukacik, et al. 2006; 439 
Oduwole, et al. 2003). 17β-HSDs play an important role in hormone sensitive cancers. 440 
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Increased expression of 17β-HSD-1 in breast cancers of post-menopausal women helps 441 
maintain high intratumoural E2 levels (Lukacik et al. 2006). Moreover, expression of 17β-442 
HSD-2 and 17β-HSD-3 mRNA is significantly higher in malignant prostatic tissues 443 
compared to normal prostate tissues (Day, et al. 2013) with one study reporting prostate 444 
cancer biopsies showing 30-fold higher mRNA expression than normal. In addition to 445 
converting androstenedione to testosterone, 17β-HSD 5 can convert E1 to E2. Inhibitors of 446 
17β-HSD 5 have been explored in castration-resistant prostate cancer and breast cancer, in 447 
the latter where androgens are not considered to play an important role (Adeniji, et al. 2013). 448 
The study found no appreciable decrease in E2 synthesis in breast cancer cell lines when 449 
treated with a 17β-HSD 5 inhibitor and only a moderate decrease in E2 synthesis in some 450 
subpopulations of prostate cancer cell lines. Interestingly, inflammation associated with 451 
tumours modulates the expression of 17β-HSD-2 and 17β-HSD-5 (and also 3β-HSD). 452 
Treatment of prostate cancer stromal cell lines PrSC with TGFβ1 showed a marked down-453 
regulation in mRNA expression of 17β-HSD-2 and 17β-HSD-5 in a dose-dependent manner 454 
(Piao, et al. 2013).  The counterintuitive action of TGFβ1 again demonstrates how little is 455 
understood about oestrogenic pathways in prostate cancer. Regardless of the mechanisms by 456 
which oestrogens become available within the prostate gland, tumour-promoting or tumour-457 
suppressing effects must be mediated by activation of oestrogen receptors (ER).  458 
 459 
Oestrogen receptors (ER) in the prostate 460 
The effects of oestrogens on tissues are mediated via activation of oestrogen receptors (ER). 461 
There are two well studied ERs; ER alpha (ERα) and ER beta (ERβ) encoded by two separate 462 
genes ESR1 and ESR2, respectively. ERα and ERβ are members of the nuclear receptor 463 
superfamily (Robinson-Rechavi, et al. 2003). When bound and activated, ERs interact 464 
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directly with the genome acting as transcription factors (or activating transcription factors) 465 
which act directly on oestrogen response elements (Deblois and Giguere 2013). As well as 466 
E2, ERs can be stimulated by phytoestrogens, and different classes of phytoestrogens have 467 
selected preferences for each type of ER. In general, phytoestrogens show agonistic activity 468 
towards ERβ at lower concentrations than towards ERα using hamster uterine cells 469 
(Takeuchi, et al. 2009). When human cells are examined, the relative binding affinity (RBA) 470 
of genistein to ERβ is approximately 20-30 times greater than for ERα as shown in MCF-7 471 
breast cancer cell lines (Pilšáková et al. 2010). The affinity of phytoestrogens for ER widely 472 
varies with most molecules having an RBA to ERβ 1000-fold lower than E2. However, 473 
molecules such as genistein and coumesterol have an RBA 100-fold lower than E2. Genistein 474 
and coumesterol are able to activate transcriptional activities of ERα and ERβ at 475 
concentrations of 1-10nM compared to physiological E2 concentrations of 20-40pM in males 476 
(Kuiper, et al. 1998; Mueller et al. 2015). Of course, the ability of phytoestrogens to bind to 477 
ER also depends on the existing levels of E1 and E2 as these molecules are direct competitors 478 
with phytoestrogens.  479 
 480 
ERs have been studied more extensively in the context of breast cancers, a neoplasm that has 481 
been likened as the sister disease to prostate cancer, especially in regards to their hormonal 482 
responses and sensitivities (Risbridger, et al. 2010). In breast cancer, activation of ERα 483 
promotes tumour growth as it initiates anti-apoptotic (Chaudhri, et al. 2014; Razandi, et al. 484 
2000) and mitogenic effects (Bhatt, et al. 2012; Yamnik and Holz 2010). This anti-apoptotic 485 
effect of ERα  makes ERα positive breast cancers more likely to metastasise (Ross-Innes, et 486 
al. 2012). In fact, a review of ERs in breast and ovarian cancers has found ERα expression 487 
correlates with worse prognosis whereas ERβ expression correlates with better clinical 488 
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outcomes (Burns and Korach 2012). Generally, ERα activation promotes proliferative 489 
pathways whereas ERβ activation leads to apoptotic pathways (Acconcia, et al. 2005).  490 
 491 
Expression of ERα and ERβ in the normal prostate has been determined as the role of 492 
oestrogens in prostatic development was identified (Ho 2004). Recently it has been reported 493 
that prostate progenitor stem cells, while lacking expression of androgen receptor, express ER 494 
abundantly. Indeed, the expression of ERβ is putatively 6-fold greater and ERα 125-fold 495 
greater in progenitor cells compared to LNCaP mature cells (Di Zazzo, et al. 2016). Although 496 
this supports the importance of oestrogens in embryonic and neonatal development of 497 
prostate gland, it has been hypothesised that lack of androgen receptor expression could be an 498 
imprint which later predisposes to CRPC in the elderly. In non-cancerous prostate ERα is 499 
predominantly expressed in the stromal compartment and ERβ is predominantly expressed in 500 
basal-epithelial cells. However in prostate cancer, ERα expression is down-regulated in 501 
stromal cells and upregulated in the cancerous epithelial cells. ERβ expression is down-502 
regulated in epithelial cells as seen by immunostaining in human prostate tissue (Yeh, et al. 503 
2014). Indeed there is evidence that down-regulation of ERβ promotes activation of NF-κB 504 
mediated by hypoxia-inducible factor 1 (HIF-1). In immortalised normal prostate epithelial 505 
cell line PNT1a, loss of ERβ using shRNA showed an increase in NF-κB mRNA expression 506 
and activity. This mirrors what is seen in high grade, late stage prostate cancer (Mak, et al. 507 
2015). Consequently, it appears that an increase in ERα expression and decrease in ERβ 508 
expression is what shifts the balance between protective effects of oestrogens and 509 
proliferative effects of oestrogens as has been suggested in other cancers (Barzi, et al. 2013; 510 
Burns and Korach 2012). Figure 3 summarises the difference in ERα and ERβ expression 511 
between non-cancerous and cancerous prostate tissue. Single nucleotide polymorphisms 512 
(SNP)  in the ER genes have been investigated and associations have been made between 513 
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certain polymorphisms and the risk of prostate cancer (Holt, et al. 2013; Jurečeková, et al. 514 
2015). In both studies, the genomes from histologically confirmed human prostate cancer 515 
samples were analysed using polymerase chain reaction restriction fragment length 516 
polymorphism (PCR-RFLP) based analysis and compared to age-matched healthy control 517 
subjects. A meta-analysis exploring the results of 24 published studies that include 518 
Caucasian, Asian and African participants concluded that  ESR1 rs9340799 polymorphism is 519 
allied to increased risk in the general population of Caucasians and Africans whereas ESR2 520 
rs1256049 polymorphisms has been linked to increased risk only in Caucasians (Fu, et al. 521 
2014).  522 
 523 
Research into ERβ has been more extensive than in ERα. McPherson et al. (2007) highlighted 524 
the potential significance of ERβ manipulation when they treated prostate hyperplasia in 525 
oestrogen depleted mice with a selective ERβ agonist and found it to induce apoptosis and 526 
shrink the size of the prostate. Hussain et al. (2012) carried forward this research and initial 527 
studies have found ERβ agonist treatment with 8β-VE2 can induce apoptosis in primary 528 
human and murine prostatic basal cells, 
 
a lineage considered to be the cells of origin for 529 
prostate cancers (Taylor, et al. 2012). The mechanism behind how ERβ activation induces 530 
apoptosis in prostate cancer cells lines may be via up-regulation of p53-upregulated 531 
modulator of apoptosis (PUMA) and consequent intrinsic caspase-9 mechanisms. Dey, et al. 532 
overexpressed ERβ in LNCaP, PC3 and 22Rv1 prostate cancer cell lines in vitro, the latter 533 
which does not express ERβ, and treated with E2 and agonist 3β-adiol. Immunofluorescence 534 
revealed that cells which expressed ERβ were more likely to undergo apoptosis following 535 
expression of PUMA independent of p53  (Dey, et al. 2014).  (Dey, et al. 2014). It has even 536 
been reported that ERβ activation impedes on the epithelial-mesenchymal transition process 537 
thereby reducing the risk of invasion and metastasis. In human tissue samples and LNCaP 538 
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and PC3 cell lines, treatment with E2 and high concentration of ERβ1 agonist 3β-adiol 539 
resulted in inhibition of VEGF and destabilisation of HIF-1 in vitro thus suppressing the 540 
factors that drive epithelial-mesenchymal transition necessary for metastasis. Furthermore, 541 
loss of ERβ1 expression by means of shRNA transfection resulted in significant increase in 542 
migration and invasion (Mak, et al. 2010). Mounting evidence also suggests that 543 
pharmaceutical targeting of ERβ pathways may be effective in treating prostate cancer. 544 
However, recently a ‘switching roles’ theory has been proposed suggesting the effects of ERβ 545 
activation switches from protective to proliferative as cancer progresses (Savoy and Ghosh 546 
2013). The theory is based on the observation that castration-resistant prostate cancers have 547 
higher expression of ERβ compared to hormone-naïve prostate cancers. It is possible that 548 
decreased levels of circulating androgens and up-regulation of androgen receptors may be 549 
important in this switch however the actual mechanisms and processes are yet unknown.  550 
 551 
Splice variants of ERβ are also important as it has been shown that at least 5 different 552 
isoforms exist, many of which are expressed in the prostate (Leung, et al. 2006). Activation 553 
of different isoforms may have opposing effects; for example ERβ1 is tumour-suppressing 554 
whereas ERβ2 is tumour-promoting in LNCaP cells (Chen, et al. 2009). In a study of primary 555 
prostate cancer samples from 144 patients who underwent radical prostatectomy, two 556 
particular isoforms ERβ2 and ERβ5 have been identified to promote invasion and metastasis 557 
of prostate cancer and thus correlate with worse outcomes while others continue to be studied 558 
(Leung, et al. 2010; Nelson, et al. 2014). Certain ERβ isoforms, such as ERβ2 and ERβ3, 559 
when activated interact with transcription factors which enable and promote the epithelial 560 
mesenchyme transition and hence might be why advanced prostate cancers have higher 561 
expression of ERβ (Leung et al. 2010). More research needs to be carried out to understand 562 
the mechanisms of the complex downstream pathways of ERβ activation in prostate cancer. 563 
Page 23 of 47
 564 
The tumour promoting effects of ERα within the prostate are not as well defined. ERα is 565 
expressed in significant quantities in the stromal tissue of prostate cancer where they have 566 
been associated with cancer-associated fibroblasts (CAF) (Slavin, et al. 2015). Da, et al. 567 
isolated CAF from adenocarcinoma of mouse prostate lentivirally transduced ERα. 568 
Conditioned media from ERα+ CAF promoted proliferation of LNCaP, PC3, C4-2 and 569 
22Rv1 cells. Furthermore, in xenograft experiments mice co-implanted with ERα+ CAF 570 
showed a higher growth rate of tumour mass compared to injection of prostate cancer cell 571 
lines alone (Da, et al. 2015). Activation of ERα on CAFs stimulates the release of tumour-572 
promoting factors which act on prostate epithelia in a paracrine manner. Slug (SNAI2), a 573 
transcription factor with anti-apoptotic pathways can repress ERα expression by binding to 574 
gene promotor regions and consequently promote epithelial-mesenchymal transition in 575 
prostate cancer cells and human breast cancer samples (Li, et al. 2015a). In contrast, 576 
downstream pathways of ERα activation can inhibit metastasis by down-regulating 577 
expression of matrix metalloproteinase 3 and upregulating expression of thrombospondin 2  578 
as seen in a range of breast cancer cell lines and LNCaP cell line, however this is not 579 
evidence in primary human prostate tissue (Li et al. 2015a). This may be an effect of ERα 580 
activation which diverts cell resources towards growth of prostate cancer rather than spread 581 
and invasion (Hanahan and Weinberg 2011). A study investigating the role of ERα in prostate 582 
cancers of PTEN-deficient mice has shown expression of ERα correlates strongly with the 583 
expression of Ki67,- a proliferative marker. In addition, inhibition and knockdown of ERα 584 
decreases proliferation but has no effect on cell viability thus the tumour mass remained 585 
static. This further demonstrates that ERα regulates cell proliferation through PI3K and 586 
MAPK signalling (Takizawa, et al. 2015).   587 
 588 
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Human trials in 1590 men with high grade intraepithelial neoplasia of the prostate has shown 589 
no significant decrease in risk of prostate cancer when treated with daily toremifene, a 590 
selective oestrogen receptor modulator (SERM) used for the treatment of metastatic breast 591 
cancer, compared with placebo. Of the 1467 men who underwent a biopsy during the three-592 
year study, cancer was detected in 34.7% in the placebo group compared to 32.3% in the 593 
treatment group (p= 0.39) (Taneja, et al. 2013). Conversely, experimental use of toremifene, 594 
in cell lines and nude mice models have suggested that ERα antagonists can repress the 595 
tumorigenicity of prostate cancer (Hariri, et al. 2015). Intriguingly, there is recent evidence 596 
that abiraterone, used frequently in advanced prostate cancer is able to activate ER. Capper, 597 
et al. demonstrated an increase in proliferation of MCF-7 and T47D breast cancer cell lines 598 
when treated with abiraterone. The proliferative effects were diminished when the cells were 599 
treated with ER antagonist ICI 182,78 (Capper, et al. 2016). ER-mediated progression of 600 
prostate cancer might thus constitute a novel mechanism of resistance to abiraterone that 601 
warrants further investigation. The signalling mechanisms of ERα and ERβ are summarised 602 
in Figure 4. 603 
 604 
In addition to the two nuclear ERs, ERα and ERβ, another relatively recently discovered ER 605 
exists. G-protein coupled oestrogen receptor (GPER), alternatively known as GPR30, is a 606 
membrane-bound receptor discovered in 1998 (O'Dowd, et al. 1998). GPER is found in 50% 607 
of breast cancers and is believed to be critically involved in how Tamoxifen (a SERM) 608 
resistance is developed (Mo, et al. 2013). Tamoxifen can bind and stimulate GPER in breast 609 
cancer (Prossnitz, et al. 2008a) activating downstream cancer promoting pathways. GPER has 610 
also been shown to be expressed in various hormone-sensitive tissues in the body including 611 
the prostate (Prins and Hu 2013; Prossnitz, et al. 2007) and has very similar affinity for E2 as 612 
ERα and ERβ with almost no interaction with androgens or glucocorticoids (Prossnitz, et al. 613 
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2008b). In addition to being activated by endogenous E2, GPER can also be activated by 614 
phytoestrogens with similar RBA as phytoestrogens have to ERβ and elicit an oestrogenic 615 
signalling pathways (Thomas and Dong 2006).  616 
 617 
Evidence of changes in GPER expression within prostate cancer is scarce, though it has been 618 
established with immunofluorescence and immunoblotting that GPER is expressed LNCaP, 619 
DU145 and PC3 cellswhich have varying degrees of invasiveness (Maier, et al. 2006). In 620 
addition, expression of GPER has been identified by immunohistochemistry and 621 
immunoblotting in prostate adenocarcinomas and in pre-neoplastic lesions in 50 patients with 622 
confirmed prostate cancer of varying grades of aggressiveness and in 5 patients with benign 623 
prostatic disease (Rago, et al. 2016). Naturally, more research has been conducted in 624 
aggressive cell lines and primary tissues. In contrast to the effects of GPER activation in 625 
breast and ovarian cancers where it promotes growth, it has been identified that treatment of 626 
castration-resistant prostate cancer with a specific GPER agonist, G1, actually inhibits the 627 
growth of prostate cancer in PC-3, DU145 and LNCaP cell lines in vitro and in vivo PC3 628 
xenografts (Chan, et al. 2010; Lam, et al. 2014). While most studies only reported tumour 629 
inhibition in castration-resistant cell lines, Lam et al. found that G1 treatment has no effect on 630 
androgen-sensitive LNCaP cells in vitro and in vivo xenograft mouse models whereas it had a 631 
significant effect on castration-resistant tumours without apparent toxicity to the host (Lam et 632 
al. 2014). Furthermore, GPER expression is significantly increased in androgen-deprived 633 
environments compared to androgen-replete milieus (Prins and Hu 2013)with increased 634 
GPER expression also evident in cells isolated from distant metastases in patients with CRPC 635 
CRPC compared to tissue from primary prostate cancers (Lam et al. 2014). Androgen 636 
receptor activation downregulates GPER expression thus explaining why expression of 637 
GPER is greater in androgen deprived environments (Lam et al. 2014).  The mechanisms by 638 
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which the GPER agonist G1 has anti-tumour effects has been explored in PC3 cell line in 639 
vitro and in vivo xenograft castrated mice models and is reported to be via up-regulation of 640 
p21 and consequent cell cycle arrest at G2 phase (Chan et al. 2010). Although GPER 641 
activation inhibits growth of prostate cancer, it increases proliferation of other tissues 642 
including testicular germ cells and urothelial cells of the bladder and urinary tract (Chevalier, 643 
et al. 2011; Huang, et al. 2015). The fact that GPER activation can have opposing effects in 644 
different tissues through the same pathway illustrates the complexity of intracellular 645 
oestrogen signalling. Figure 4 grossly summarises GPER signalling pathways that have thus 646 
far been identified in prostate cancer. 647 
 648 
Conclusion 649 
This review has presented evidence that suggests an imbalance of circulating oestrogens and 650 
androgens may be responsible for changes to the development and progression of prostate 651 
cancer. In addition to endogenous oestrogen availability, exposure to exogenous oestrogens 652 
in the form of phytoestrogens may also have a profound effect. However, there is substantial 653 
evidence that intratumoural synthesis of oestrogens, and indeed androgens, plays a significant 654 
role as the prostate is endowed with the ability to express key enzymes required for oestrogen 655 
synthesis. There is a relationship between stage of disease and level of expression of these 656 
enzymes, as is evident from the emergence of resistance to anti-androgen therapy further 657 
supports this hypothesis.    658 
 659 
Changes in the expression pattern of ERα and ERβ greatly affect whether oestrogens are 660 
tumour promoting or tumour suppressing. In normal prostate and during early stages of 661 
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prostate cancer where ERβ is the prominent ER, oestrogens may be beneficial as ERβ 662 
activation initiates apoptotic pathways. Perhaps this is why a lifetime of increased 663 
phytoestrogen consumption can reduce the risk of prostate cancer development. In late stage 664 
prostate cancer where ERα is the dominating ER within the prostate, oestrogens are 665 
deleterious as ERα activation regulates cell proliferation through PI3K and MAPK signalling. 666 
Activation of GPER inhibits growth of prostate cancer however, GPER is not uniformly 667 
expressed in all prostate cancer and thus any GPER targeted therapy will be of benefit to a 668 
limited number of patients. Figure 5 summarises how the expression of ERs change during 669 
the progression of prostate cancer.  670 
 671 
Before any definitive conclusions can be drawn over whether oestrogens are good or bad for 672 
prostate cancer, further research has to be conducted exploring the signalling pathways of ER 673 
within prostate tissue. In addition an understanding of the mechanisms behind abiraterone 674 
(Romanel, et al. 2015) and enzalutamide resistance (Claessens, et al. 2014), and whether this 675 
is linked to altered androgen and oestrogen metabolism, will be required before the next big 676 
step is taken towards development of endocrine therapy for prostate cancer.  677 
 678 
 679 
 680 
 681 
 682 
  683 
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Figure Legends 
 
Figure 1: Molecular similarities between phytoestrogens and E2. E2 contains the 
cyclopenta[α]phenanthrene ring structure common to all steroid molecules. Isoflavonesand 
coumestans are two common categories of phytoestrogens and have a molecular structure 
similar to E2. As a result phytoestrogens can also bind and activate the oestrogen receptors. 
 
Figure 2: Oestrogen and Androgen synthesis pathways.  
Intratumoural E2 can be formed from desulfation and reduction of circulating oestrone-
sulphate (E1S) by steroid sulphatase (STS) and 17β-hydroxysteroid dehydrogenase (HSD). 
Alternatively, oestrogens can be produced from androstenedione or testosterone by 
aromatase. Aromatase competes with 5α-reductase (SRD5A1), responsible for potentiating 
androgens, for these substrates. DHEA, the precursor for androstenedione, is most likely 
derived from the large pool of circulating DHEAS by STS, as intratumoural synthesis from 
progestogens remains disputable.  
 
Figure 3: The expression of ERα and ERβ changes during prostate cancer progression. 
During development of prostate cancer the ERβ isoform is downregulated in epithelial cells. 
On the other hand, ERα is upregulated in tumour cells as well as the surrounding 
environment. The remainder of the ‘normal’ prostate retains its existing expression of ERα 
and ERβ 
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Figure 4: Signalling pathways in prostate cancer through ERα, ERβ and GPER. ERα 
and ERβ bind to the oestrogen response elements (ERE) of DNA and regulate transcription. 
Activation of ERα induces mitogenic pathways via PI3K which in turn promotes HIF-1α 
which activates anti-apoptotic pathways; whereas activation of ERβ induces apoptosis, cell 
cycle arrest and inhibits dedifferentiation pathways. GPER activation in prostate cancer is 
anti-tumourigenic as it upregulates p21 and induces cell cycle arrest. 
 
Figure 5: The altered expression of ERs during prostate cancer development. Changes in 
ERα and ERβ have been studied throughout the evolution of prostate cancer; however, 
expression of GPER in normal prostate and early stages of prostate cancer is currently 
unknown. 
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